Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthF. Michael Yakes, Alison Joly|Molecular Cancer Therapeutics|2011Cited by 1.3k